ID   EPHB4_HUMAN             Reviewed;         987 AA.
AC   P54760; B5A970; B5A971; B5A972; Q7Z635; Q9BTA5; Q9BXP0;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   18-OCT-2001, sequence version 2.
DT   12-OCT-2022, entry version 227.
DE   RecName: Full=Ephrin type-B receptor 4;
DE            EC=2.7.10.1;
DE   AltName: Full=Hepatoma transmembrane kinase;
DE   AltName: Full=Tyrosine-protein kinase TYRO11;
DE   Flags: Precursor;
GN   Name=EPHB4; Synonyms=HTK, MYK1, TYRO11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION,
RP   AUTOPHOSPHORYLATION, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=8188704; DOI=10.1016/s0021-9258(17)36776-5;
RA   Bennett B.D., Wang Z., Kuang W.J., Wang A., Groopman J.E., Goeddel D.V.,
RA   Scadden D.T.;
RT   "Cloning and characterization of HTK, a novel transmembrane tyrosine kinase
RT   of the EPH subfamily.";
RL   J. Biol. Chem. 269:14211-14218(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11239002; DOI=10.1093/nar/29.6.1352;
RA   Wilson M.D., Riemer C., Martindale D.W., Schnupf P., Boright A.P.,
RA   Cheung T.L., Hardy D.M., Schwartz S., Scherer S.W., Tsui L.-C., Miller W.,
RA   Koop B.F.;
RT   "Comparative analysis of the gene-dense ACHE/TFR2 region on human
RT   chromosome 7q22 with the orthologous region on mouse chromosome 5.";
RL   Nucleic Acids Res. 29:1352-1365(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4), AND ALTERNATIVE SPLICING.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT ARG-162.
RC   TISSUE=Ovary, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NOMENCLATURE.
RX   PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [6]
RP   FUNCTION IN ANGIOGENESIS, FUNCTION IN CELL ADHESION, AND FUNCTION IN CELL
RP   MIGRATION.
RX   PubMed=12734395; DOI=10.1242/jcs.00426;
RA   Fueller T., Korff T., Kilian A., Dandekar G., Augustin H.G.;
RT   "Forward EphB4 signaling in endothelial cells controls cellular repulsion
RT   and segregation from ephrinB2 positive cells.";
RL   J. Cell Sci. 116:2461-2470(2003).
RN   [7]
RP   FUNCTION IN ANGIOGENESIS.
RX   PubMed=16424904; DOI=10.1038/sj.emboj.7600949;
RA   Erber R., Eichelsbacher U., Powajbo V., Korn T., Djonov V., Lin J.,
RA   Hammes H.P., Grobholz R., Ullrich A., Vajkoczy P.;
RT   "EphB4 controls blood vascular morphogenesis during postnatal
RT   angiogenesis.";
RL   EMBO J. 25:628-641(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-911 AND THR-976, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-976, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-911; THR-976 AND TYR-987, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-769; SER-770 AND THR-976, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-943, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 17-196 IN COMPLEX WITH EFNB2,
RP   MUTAGENESIS OF LEU-95, AND DISULFIDE BOND.
RX   PubMed=16867992; DOI=10.1074/jbc.m605766200;
RA   Chrencik J.E., Brooun A., Kraus M.L., Recht M.I., Kolatkar A.R., Han G.W.,
RA   Seifert J.M., Widmer H., Auer M., Kuhn P.;
RT   "Structural and biophysical characterization of the EphB4*ephrinB2 protein-
RT   protein interaction and receptor specificity.";
RL   J. Biol. Chem. 281:28185-28192(2006).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 17-196 IN COMPLEX WITH
RP   ANTAGONISTIC PEPTIDE, AND DISULFIDE BOND.
RX   PubMed=16472751; DOI=10.1016/j.str.2005.11.011;
RA   Chrencik J.E., Brooun A., Recht M.I., Kraus M.L., Koolpe M., Kolatkar A.R.,
RA   Bruce R.H., Martiny-Baron G., Widmer H., Pasquale E.B., Kuhn P.;
RT   "Structure and thermodynamic characterization of the EphB4/Ephrin-B2
RT   antagonist peptide complex reveals the determinants for receptor
RT   specificity.";
RL   Structure 14:321-330(2006).
RN   [17]
RP   STRUCTURE BY NMR OF 434-529.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the second FN3 domain from human ephrin type-B
RT   receptor 4.";
RL   Submitted (JUL-2007) to the PDB data bank.
RN   [18]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-67; ILE-113; LEU-346; VAL-371; GLU-576;
RP   HIS-678; THR-882; TRP-889 AND ASP-890.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [19]
RP   INVOLVEMENT IN LMPHM7, VARIANTS LMPHM7 GLN-739 AND SER-782,
RP   CHARACTERIZATION OF VARIANTS LMPHM7 GLU-739 AND SER-782, AND FUNCTION.
RX   PubMed=27400125; DOI=10.1172/jci85794;
RA   Martin-Almedina S., Martinez-Corral I., Holdhus R., Vicente A., Fotiou E.,
RA   Lin S., Petersen K., Simpson M.A., Hoischen A., Gilissen C., Jeffery H.,
RA   Atton G., Karapouliou C., Brice G., Gordon K., Wiseman J.W., Wedin M.,
RA   Rockson S.G., Jeffery S., Mortimer P.S., Snyder M.P., Berland S.,
RA   Mansour S., Makinen T., Ostergaard P.;
RT   "EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic-
RT   related hydrops fetalis.";
RL   J. Clin. Invest. 126:3080-3088(2016).
RN   [20]
RP   VARIANTS CMAVM2 LYS-59; PRO-74; TYR-115 DEL; 130-TRP--TYR-987 DEL;
RP   161-VAL-LYS-162 DELINS LEU; PRO-187; 244-GLN--TYR-987 DEL; ARG-268;
RP   352-ARG--TYR-987 DEL; 375-GLY--TYR-987 DEL; 431-ARG--TYR-987 DEL; GLY-469;
RP   ARG-516; 520-GLN--TYR-987 DEL; 596-TYR--TYR-987 DEL; TRP-656; LYS-664;
RP   THR-725; 739-ARG--TYR-987 DEL; ASP-745; ARG-789; SER-789; 806-TYR--TYR-987
RP   DEL; ARG-807; LEU-820; THR-820; TRP-838; ARG-845; TYR-856; TRP-864 AND
RP   PRO-874, CHARACTERIZATION OF VARIANTS CMAVM2 LYS-664; TRP-838; ARG-845 AND
RP   TRP-864, INVOLVEMENT IN CMAVM2, AND SUBCELLULAR LOCATION.
RX   PubMed=28687708; DOI=10.1161/circulationaha.116.026886;
RA   Amyere M., Revencu N., Helaers R., Pairet E., Baselga E., Cordisco M.,
RA   Chung W., Dubois J., Lacour J.P., Martorell L., Mazereeuw-Hautier J.,
RA   Pyeritz R.E., Amor D.J., Bisdorff A., Blei F., Bombei H., Dompmartin A.,
RA   Brooks D., Dupont J., Gonzalez-Ensenat M.A., Frieden I., Gerard M.,
RA   Kvarnung M., Hanson-Kahn A.K., Hudgins L., Leaute-Labreze C., McCuaig C.,
RA   Metry D., Parent P., Paul C., Petit F., Phan A., Quere I., Salhi A.,
RA   Turner A., Vabres P., Vicente A., Wargon O., Watanabe S., Weibel L.,
RA   Wilson A., Willing M., Mulliken J.B., Boon L.M., Vikkula M.;
RT   "Germline loss-of-function mutations in EPHB4 cause a second form of
RT   capillary malformation-arteriovenous malformation (CM-AVM2) deregulating
RT   RAS-MAPK signaling.";
RL   Circulation 136:1037-1048(2017).
RN   [21]
RP   VARIANT CMAVM2 GLY-802, AND INVOLVEMENT IN CMAVM2.
RX   PubMed=28730721; DOI=10.1111/pde.13208;
RA   Yu J., Streicher J.L., Medne L., Krantz I.D., Yan A.C.;
RT   "EPHB4 mutation implicated in capillary malformation-arteriovenous
RT   malformation syndrome: A case report.";
RL   Pediatr. Dermatol. 34:E227-E230(2017).
RN   [22]
RP   VARIANTS CMAVM2 ARG-107 AND GLU-870, AND INVOLVEMENT IN CMAVM2.
RX   PubMed=29444212; DOI=10.1093/brain/awy020;
RA   Vivanti A., Ozanne A., Grondin C., Saliou G., Quevarec L., Maurey H.,
RA   Aubourg P., Benachi A., Gut M., Gut I., Martinovic J., Senat M.V., Tawk M.,
RA   Melki J.;
RT   "Loss of function mutations in EPHB4 are responsible for vein of Galen
RT   aneurysmal malformation.";
RL   Brain 141:979-988(2018).
RN   [23]
RP   VARIANT GLY-509, CHARACTERIZATION OF VARIANT GLY-509, VARIANTS CMAVM2
RP   ASN-650 AND LEU-867, CHARACTERIZATION OF VARIANTS CMAVM2 ASN-650 AND
RP   LEU-867, INVOLVEMENT IN CMAVM2, FUNCTION, AND INTERACTION WITH RASA1.
RX   PubMed=30578106; DOI=10.1016/j.neuron.2018.11.041;
RA   Duran D., Zeng X., Jin S.C., Choi J., Nelson-Williams C., Yatsula B.,
RA   Gaillard J., Furey C.G., Lu Q., Timberlake A.T., Dong W., Sorscher M.A.,
RA   Loring E., Klein J., Allocco A., Hunt A., Conine S., Karimy J.K.,
RA   Youngblood M.W., Zhang J., DiLuna M.L., Matouk C.C., Mane S.,
RA   Tikhonova I.R., Castaldi C., Lopez-Giraldez F., Knight J., Haider S.,
RA   Soban M., Alper S.L., Komiyama M., Ducruet A.F., Zabramski J.M., Dardik A.,
RA   Walcott B.P., Stapleton C.J., Aagaard-Kienitz B., Rodesch G., Jackson E.,
RA   Smith E.R., Orbach D.B., Berenstein A., Bilguvar K., Vikkula M., Gunel M.,
RA   Lifton R.P., Kahle K.T.;
RT   "Mutations in chromatin modifier and ephrin signaling genes in vein of
RT   Galen malformation.";
RL   Neuron 101:429-443(2019).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously
CC       transmembrane ephrin-B family ligands residing on adjacent cells,
CC       leading to contact-dependent bidirectional signaling into neighboring
CC       cells. The signaling pathway downstream of the receptor is referred to
CC       as forward signaling while the signaling pathway downstream of the
CC       ephrin ligand is referred to as reverse signaling. Together with its
CC       cognate ligand/functional ligand EFNB2 it is involved in the regulation
CC       of cell adhesion and migration, and plays a central role in heart
CC       morphogenesis, angiogenesis and blood vessel remodeling and
CC       permeability. EPHB4-mediated forward signaling controls cellular
CC       repulsion and segregation from EFNB2-expressing cells.
CC       {ECO:0000269|PubMed:12734395, ECO:0000269|PubMed:16424904,
CC       ECO:0000269|PubMed:27400125, ECO:0000269|PubMed:30578106}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer
CC       is composed of an ephrin dimer and a receptor dimer. Oligomerization is
CC       probably required to induce biological responses (By similarity).
CC       Interacts with RASA1; the interaction depends on EPHB4 tyrosine-
CC       phosphorylation (PubMed:30578106). {ECO:0000250,
CC       ECO:0000269|PubMed:30578106}.
CC   -!- INTERACTION:
CC       P54760; P52799: EFNB2; NbExp=5; IntAct=EBI-702121, EBI-7532268;
CC       P54760; P54756: EPHA5; NbExp=2; IntAct=EBI-702121, EBI-1383718;
CC       P54760; Q9UF33: EPHA6; NbExp=2; IntAct=EBI-702121, EBI-3950019;
CC       P54760; Q15375: EPHA7; NbExp=3; IntAct=EBI-702121, EBI-1383428;
CC       P54760; P01588: EPO; NbExp=6; IntAct=EBI-702121, EBI-1027362;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28687708,
CC       ECO:0000269|PubMed:8188704}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:8188704}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P54760-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P54760-2; Sequence=VSP_056024, VSP_056025;
CC       Name=3;
CC         IsoId=P54760-3; Sequence=VSP_056020, VSP_056021;
CC       Name=4;
CC         IsoId=P54760-4; Sequence=VSP_056022, VSP_056023;
CC   -!- TISSUE SPECIFICITY: Abundantly expressed in placenta but also detected
CC       in kidney, liver, lung, pancreas, skeletal muscle and heart. Expressed
CC       in primitive and myeloid, but not lymphoid, hematopoietic cells. Also
CC       observed in cell lines derived from liver, breast, colon, lung,
CC       melanocyte and cervix. {ECO:0000269|PubMed:8188704}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal heart, lung, liver and to a
CC       lower extent in brain. Not expressed in adult brain.
CC       {ECO:0000269|PubMed:8188704}.
CC   -!- PTM: Phosphorylated; autophosphorylation is stimulated by EFNB2.
CC   -!- DISEASE: Lymphatic malformation 7 (LMPHM7) [MIM:617300]: A form of
CC       primary lymphedema, a disease characterized by swelling of body parts
CC       due to developmental anomalies and functional defects of the lymphatic
CC       system. Patients with lymphedema may suffer from recurrent local
CC       infections. LMPHM7 is an autosomal dominant form with variable
CC       expressivity. Some individuals present with severe non-immune hydrops
CC       fetalis, which may cause perinatal demise or fully resolve after the
CC       neonatal period. Others present with no edema and have milder clinical
CC       features, such as atrial septal defect or varicose veins as adults.
CC       {ECO:0000269|PubMed:27400125}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Capillary malformation-arteriovenous malformation 2 (CMAVM2)
CC       [MIM:618196]: An autosomal dominant disorder characterized by multiple,
CC       round to oval or more irregularly shaped macules that are pinkish red
CC       in color and are randomly distributed across the body. These capillary
CC       malformations are associated with either arteriovenous malformation,
CC       arteriovenous fistula, or Parkes Weber syndrome.
CC       {ECO:0000269|PubMed:28687708, ECO:0000269|PubMed:28730721,
CC       ECO:0000269|PubMed:29444212, ECO:0000269|PubMed:30578106}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U07695; AAA20598.1; -; mRNA.
DR   EMBL; AF312032; AAK21010.1; -; Genomic_DNA.
DR   EMBL; EU826608; ACF47644.1; -; mRNA.
DR   EMBL; EU826609; ACF47645.1; -; mRNA.
DR   EMBL; EU826610; ACF47646.1; -; mRNA.
DR   EMBL; BC004264; AAH04264.1; -; mRNA.
DR   EMBL; BC052804; AAH52804.1; -; mRNA.
DR   CCDS; CCDS5706.1; -. [P54760-1]
DR   PIR; A54092; A54092.
DR   RefSeq; NP_004435.3; NM_004444.4. [P54760-1]
DR   PDB; 2BBA; X-ray; 1.65 A; A=17-196.
DR   PDB; 2E7H; NMR; -; A=434-529.
DR   PDB; 2HLE; X-ray; 2.05 A; A=17-196.
DR   PDB; 2QKQ; X-ray; 2.10 A; A/B=896-977.
DR   PDB; 2VWU; X-ray; 2.00 A; A=598-899.
DR   PDB; 2VWV; X-ray; 1.90 A; A=598-899.
DR   PDB; 2VWW; X-ray; 1.90 A; A=598-899.
DR   PDB; 2VWX; X-ray; 1.65 A; A=598-899.
DR   PDB; 2VWY; X-ray; 1.65 A; A=598-899.
DR   PDB; 2VWZ; X-ray; 1.65 A; A=598-899.
DR   PDB; 2VX0; X-ray; 2.10 A; A=598-899.
DR   PDB; 2VX1; X-ray; 1.65 A; A=598-899.
DR   PDB; 2X9F; X-ray; 1.75 A; A=598-899.
DR   PDB; 2XVD; X-ray; 1.70 A; A=598-899.
DR   PDB; 2YN8; X-ray; 2.11 A; A/B=598-892.
DR   PDB; 3ZEW; X-ray; 2.50 A; A/B=598-892.
DR   PDB; 4AW5; X-ray; 2.33 A; A=605-890.
DR   PDB; 4BB4; X-ray; 1.65 A; A=598-899.
DR   PDB; 6FNI; X-ray; 1.47 A; A=598-892.
DR   PDB; 6FNJ; X-ray; 1.24 A; A/B=598-892.
DR   PDB; 6FNK; X-ray; 1.05 A; A=598-892.
DR   PDB; 6FNL; X-ray; 1.27 A; A=598-892.
DR   PDB; 6FNM; X-ray; 1.16 A; A=598-892.
DR   PDBsum; 2BBA; -.
DR   PDBsum; 2E7H; -.
DR   PDBsum; 2HLE; -.
DR   PDBsum; 2QKQ; -.
DR   PDBsum; 2VWU; -.
DR   PDBsum; 2VWV; -.
DR   PDBsum; 2VWW; -.
DR   PDBsum; 2VWX; -.
DR   PDBsum; 2VWY; -.
DR   PDBsum; 2VWZ; -.
DR   PDBsum; 2VX0; -.
DR   PDBsum; 2VX1; -.
DR   PDBsum; 2X9F; -.
DR   PDBsum; 2XVD; -.
DR   PDBsum; 2YN8; -.
DR   PDBsum; 3ZEW; -.
DR   PDBsum; 4AW5; -.
DR   PDBsum; 4BB4; -.
DR   PDBsum; 6FNI; -.
DR   PDBsum; 6FNJ; -.
DR   PDBsum; 6FNK; -.
DR   PDBsum; 6FNL; -.
DR   PDBsum; 6FNM; -.
DR   AlphaFoldDB; P54760; -.
DR   BMRB; P54760; -.
DR   SMR; P54760; -.
DR   BioGRID; 108364; 105.
DR   IntAct; P54760; 59.
DR   MINT; P54760; -.
DR   STRING; 9606.ENSP00000350896; -.
DR   BindingDB; P54760; -.
DR   ChEMBL; CHEMBL5147; -.
DR   DrugBank; DB07256; 3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE.
DR   DrugBank; DB07252; 3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB07251; N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE.
DR   DrugBank; DB07250; N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE.
DR   DrugBank; DB07253; N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine.
DR   DrugBank; DB07255; N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE.
DR   DrugBank; DB07249; N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine.
DR   DrugBank; DB07254; N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE.
DR   DrugBank; DB11973; Tesevatinib.
DR   DrugCentral; P54760; -.
DR   GuidetoPHARMACOLOGY; 1833; -.
DR   TCDB; 8.A.23.1.15; the basigin (basigin) family.
DR   GlyConnect; 1214; 3 N-Linked glycans (1 site).
DR   GlyGen; P54760; 3 sites, 3 N-linked glycans (1 site).
DR   iPTMnet; P54760; -.
DR   PhosphoSitePlus; P54760; -.
DR   SwissPalm; P54760; -.
DR   BioMuta; EPHB4; -.
DR   DMDM; 19860819; -.
DR   DOSAC-COBS-2DPAGE; P54760; -.
DR   CPTAC; CPTAC-2788; -.
DR   EPD; P54760; -.
DR   jPOST; P54760; -.
DR   MassIVE; P54760; -.
DR   MaxQB; P54760; -.
DR   PaxDb; P54760; -.
DR   PeptideAtlas; P54760; -.
DR   PRIDE; P54760; -.
DR   ProteomicsDB; 56715; -. [P54760-1]
DR   Antibodypedia; 4623; 731 antibodies from 40 providers.
DR   CPTC; P54760; 2 antibodies.
DR   DNASU; 2050; -.
DR   Ensembl; ENST00000358173.8; ENSP00000350896.3; ENSG00000196411.10. [P54760-1]
DR   Ensembl; ENST00000616502.4; ENSP00000482702.1; ENSG00000196411.10. [P54760-3]
DR   GeneID; 2050; -.
DR   KEGG; hsa:2050; -.
DR   MANE-Select; ENST00000358173.8; ENSP00000350896.3; NM_004444.5; NP_004435.3.
DR   UCSC; uc011kkg.2; human. [P54760-1]
DR   CTD; 2050; -.
DR   DisGeNET; 2050; -.
DR   GeneCards; EPHB4; -.
DR   GeneReviews; EPHB4; -.
DR   HGNC; HGNC:3395; EPHB4.
DR   HPA; ENSG00000196411; Low tissue specificity.
DR   MalaCards; EPHB4; -.
DR   MIM; 600011; gene.
DR   MIM; 617300; phenotype.
DR   MIM; 618196; phenotype.
DR   neXtProt; NX_P54760; -.
DR   NIAGADS; ENSG00000196411; -.
DR   OpenTargets; ENSG00000196411; -.
DR   Orphanet; 137667; Capillary malformation-arteriovenous malformation.
DR   Orphanet; 90186; Meige disease.
DR   Orphanet; 1053; Vein of Galen aneurysmal malformation.
DR   PharmGKB; PA27827; -.
DR   VEuPathDB; HostDB:ENSG00000196411; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   GeneTree; ENSGT00940000160057; -.
DR   HOGENOM; CLU_000288_141_3_1; -.
DR   InParanoid; P54760; -.
DR   OMA; TAHWLRT; -.
DR   OrthoDB; 933071at2759; -.
DR   PhylomeDB; P54760; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P54760; -.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P54760; -.
DR   SIGNOR; P54760; -.
DR   BioGRID-ORCS; 2050; 13 hits in 1109 CRISPR screens.
DR   ChiTaRS; EPHB4; human.
DR   EvolutionaryTrace; P54760; -.
DR   GeneWiki; EPH_receptor_B4; -.
DR   GenomeRNAi; 2050; -.
DR   Pharos; P54760; Tchem.
DR   PRO; PR:P54760; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P54760; protein.
DR   Bgee; ENSG00000196411; Expressed in olfactory bulb and 207 other tissues.
DR   ExpressionAtlas; P54760; baseline and differential.
DR   Genevisible; P54760; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005003; F:ephrin receptor activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central.
DR   GO; GO:0001525; P:angiogenesis; ISS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; IDA:UniProtKB.
DR   GO; GO:0002042; P:cell migration involved in sprouting angiogenesis; IDA:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0003007; P:heart morphogenesis; ISS:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd10474; EphR_LBD_B4; 1.
DR   CDD; cd00063; FN3; 2.
DR   CDD; cd09554; SAM_EPH-B4; 1.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR037636; EPH-B4_SAM.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034290; EphB4_rcpt_lig-bd.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF07699; Ephrin_rec_like; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; ATP-binding;
KW   Cell membrane; Developmental protein; Disease variant; Disulfide bond;
KW   Glycoprotein; Kinase; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Receptor; Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL          1..15
FT                   /evidence="ECO:0000255"
FT   CHAIN           16..987
FT                   /note="Ephrin type-B receptor 4"
FT                   /id="PRO_0000016834"
FT   TOPO_DOM        16..539
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        540..560
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        561..987
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          17..202
FT                   /note="Eph LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00883"
FT   DOMAIN          323..432
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          436..529
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          615..899
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          907..971
FT                   /note="SAM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00184"
FT   REGION          965..987
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           985..987
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        740
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         621..629
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         647
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         769
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         770
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         911
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         943
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         976
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         987
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   CARBOHYD        203
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        335
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        426
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        61..184
FT   DISULFID        97..107
FT   VAR_SEQ         270..306
FT                   /note="ACAQGTFKPLSGEGSCQPCPANSHSNTIGSAVCQCRV -> GRRGSQQRAVP
FT                   EDVRKPGRAAGAEAGSQLPGAGTGAL (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056020"
FT   VAR_SEQ         307..987
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056021"
FT   VAR_SEQ         406..414
FT                   /note="VTALNGVSS -> YLLQCLTSG (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056022"
FT   VAR_SEQ         415..987
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056023"
FT   VAR_SEQ         507..516
FT                   /note="VRARSEAGYG -> RARAGGSSWP (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056024"
FT   VAR_SEQ         517..987
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056025"
FT   VARIANT         59
FT                   /note="E -> K (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs1584667224)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081689"
FT   VARIANT         67
FT                   /note="P -> L (in dbSNP:rs34653459)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042181"
FT   VARIANT         74
FT                   /note="R -> P (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs61735971)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081690"
FT   VARIANT         107
FT                   /note="C -> R (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs1562974383)"
FT                   /evidence="ECO:0000269|PubMed:29444212"
FT                   /id="VAR_081691"
FT   VARIANT         113
FT                   /note="V -> I (in dbSNP:rs55866373)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042182"
FT   VARIANT         115
FT                   /note="Missing (in CMAVM2; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081692"
FT   VARIANT         130..987
FT                   /note="Missing (in CMAVM2)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081693"
FT   VARIANT         161..162
FT                   /note="VK -> L (in CMAVM2; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081694"
FT   VARIANT         162
FT                   /note="K -> R (in dbSNP:rs17854760)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_071163"
FT   VARIANT         187
FT                   /note="L -> P (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs1584666053)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081695"
FT   VARIANT         244..987
FT                   /note="Missing (in CMAVM2)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081696"
FT   VARIANT         268
FT                   /note="C -> R (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs201816920)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081697"
FT   VARIANT         346
FT                   /note="P -> L (in a metastatic melanoma sample; somatic
FT                   mutation; dbSNP:rs267601191)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042183"
FT   VARIANT         352..987
FT                   /note="Missing (in CMAVM2)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081698"
FT   VARIANT         371
FT                   /note="A -> V (in dbSNP:rs55720981)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042184"
FT   VARIANT         375..987
FT                   /note="Missing (in CMAVM2)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081699"
FT   VARIANT         431..987
FT                   /note="Missing (in CMAVM2)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081700"
FT   VARIANT         469
FT                   /note="V -> G (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs1584662591)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081701"
FT   VARIANT         509
FT                   /note="A -> G (does not affect tyrosine phosphorylation;
FT                   does not affect interaction with RASA1; dbSNP:rs146937374)"
FT                   /evidence="ECO:0000269|PubMed:30578106"
FT                   /id="VAR_081702"
FT   VARIANT         516
FT                   /note="G -> R (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs776305185)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081703"
FT   VARIANT         520..987
FT                   /note="Missing (in CMAVM2)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081704"
FT   VARIANT         576
FT                   /note="D -> E (in dbSNP:rs36050247)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042185"
FT   VARIANT         596..987
FT                   /note="Missing (in CMAVM2)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081705"
FT   VARIANT         650
FT                   /note="K -> N (in CMAVM2; highly decreased tyrosine
FT                   phosphorylation; highly decreased interaction with RASA1;
FT                   dbSNP:rs1584658113)"
FT                   /evidence="ECO:0000269|PubMed:30578106"
FT                   /id="VAR_081706"
FT   VARIANT         656
FT                   /note="R -> W (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs745584371)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081707"
FT   VARIANT         664
FT                   /note="E -> K (in CMAVM2; the mutant protein is not
FT                   detected by Western blot; loss of localization to cell
FT                   membrane; dbSNP:rs1562969219)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081708"
FT   VARIANT         678
FT                   /note="R -> H (in dbSNP:rs55692440)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042186"
FT   VARIANT         725
FT                   /note="A -> T (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs1159930961)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081709"
FT   VARIANT         739..987
FT                   /note="Missing (in CMAVM2)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081710"
FT   VARIANT         739
FT                   /note="R -> Q (in LMPHM7; loss of kinase activity;
FT                   dbSNP:rs1057519263)"
FT                   /evidence="ECO:0000269|PubMed:27400125"
FT                   /id="VAR_078063"
FT   VARIANT         745
FT                   /note="N -> D (in CMAVM2; dbSNP:rs1584654433)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081711"
FT   VARIANT         782
FT                   /note="I -> S (in LMPHM7; loss of kinase activity;
FT                   dbSNP:rs1057519264)"
FT                   /evidence="ECO:0000269|PubMed:27400125"
FT                   /id="VAR_078064"
FT   VARIANT         789
FT                   /note="P -> R (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs753075600)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081712"
FT   VARIANT         789
FT                   /note="P -> S (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs1417508111)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081713"
FT   VARIANT         802
FT                   /note="D -> G (in CMAVM2; dbSNP:rs776410552)"
FT                   /evidence="ECO:0000269|PubMed:28730721"
FT                   /id="VAR_081714"
FT   VARIANT         806..987
FT                   /note="Missing (in CMAVM2)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081715"
FT   VARIANT         807
FT                   /note="G -> R (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs1330628156)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081716"
FT   VARIANT         820
FT                   /note="P -> L (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs1584653650)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081717"
FT   VARIANT         820
FT                   /note="P -> T (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs1584653653)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081718"
FT   VARIANT         838
FT                   /note="R -> W (in CMAVM2; the mutant protein is not
FT                   detected by Western blot; loss of localization to cell
FT                   membrane; dbSNP:rs764827256)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081719"
FT   VARIANT         845
FT                   /note="C -> R (in CMAVM2; the mutant protein is not
FT                   detected by Western blot; loss of localization to cell
FT                   membrane; dbSNP:rs1584653054)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081720"
FT   VARIANT         856
FT                   /note="C -> Y (in CMAVM2; dbSNP:rs1584653005)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081721"
FT   VARIANT         864
FT                   /note="R -> W (in CMAVM2; the mutant protein is not
FT                   detected by Western blot; loss of localization to cell
FT                   membrane; dbSNP:rs769965440)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081722"
FT   VARIANT         867
FT                   /note="F -> L (in CMAVM2; loss of tyrosine phosphorylation;
FT                   loss of interaction with RASA1; dbSNP:rs1584652949)"
FT                   /evidence="ECO:0000269|PubMed:30578106"
FT                   /id="VAR_081723"
FT   VARIANT         870
FT                   /note="V -> E (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs1584652920)"
FT                   /evidence="ECO:0000269|PubMed:29444212"
FT                   /id="VAR_081724"
FT   VARIANT         874
FT                   /note="L -> P (in CMAVM2; unknown pathological
FT                   significance; dbSNP:rs1584652900)"
FT                   /evidence="ECO:0000269|PubMed:28687708"
FT                   /id="VAR_081725"
FT   VARIANT         882
FT                   /note="A -> T (in dbSNP:rs34918225)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042187"
FT   VARIANT         889
FT                   /note="R -> W (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs762016655)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042188"
FT   VARIANT         890
FT                   /note="E -> D (in dbSNP:rs35638378)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042189"
FT   MUTAGEN         95
FT                   /note="L->R: Reduces binding affinity for EFNB2."
FT                   /evidence="ECO:0000269|PubMed:16867992"
FT   CONFLICT        62
FT                   /note="D -> E (in Ref. 1; AAA20598)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        308
FT                   /note="Y -> D (in Ref. 1; AAA20598)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        464
FT                   /note="V -> W (in Ref. 1; AAA20598)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        926..927
FT                   /note="ES -> AR (in Ref. 1; AAA20598)"
FT                   /evidence="ECO:0000305"
FT   STRAND          17..22
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   HELIX           23..25
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   STRAND          33..36
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   STRAND          43..48
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   STRAND          54..61
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   STRAND          63..65
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   STRAND          70..74
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   STRAND          84..95
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   HELIX           97..99
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   STRAND          109..121
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   STRAND          130..132
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   STRAND          135..142
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   STRAND          147..150
FT                   /evidence="ECO:0007829|PDB:2HLE"
FT   TURN            151..153
FT                   /evidence="ECO:0007829|PDB:2HLE"
FT   STRAND          154..156
FT                   /evidence="ECO:0007829|PDB:2HLE"
FT   STRAND          160..166
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   STRAND          171..182
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   STRAND          184..196
FT                   /evidence="ECO:0007829|PDB:2BBA"
FT   STRAND          441..446
FT                   /evidence="ECO:0007829|PDB:2E7H"
FT   STRAND          449..453
FT                   /evidence="ECO:0007829|PDB:2E7H"
FT   STRAND          460..462
FT                   /evidence="ECO:0007829|PDB:2E7H"
FT   STRAND          466..473
FT                   /evidence="ECO:0007829|PDB:2E7H"
FT   TURN            479..481
FT                   /evidence="ECO:0007829|PDB:2E7H"
FT   STRAND          482..496
FT                   /evidence="ECO:0007829|PDB:2E7H"
FT   STRAND          503..510
FT                   /evidence="ECO:0007829|PDB:2E7H"
FT   HELIX           612..614
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   STRAND          615..623
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   STRAND          625..634
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   STRAND          637..639
FT                   /evidence="ECO:0007829|PDB:6FNJ"
FT   STRAND          642..649
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   HELIX           655..668
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   STRAND          679..683
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   STRAND          685..694
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   HELIX           701..707
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   TURN            708..710
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   HELIX           714..733
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   HELIX           743..745
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   STRAND          746..748
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   STRAND          754..756
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   STRAND          761..763
FT                   /evidence="ECO:0007829|PDB:6FNI"
FT   HELIX           765..767
FT                   /evidence="ECO:0007829|PDB:2VWX"
FT   HELIX           784..786
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   HELIX           789..794
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   HELIX           799..814
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   TURN            815..817
FT                   /evidence="ECO:0007829|PDB:6FNI"
FT   TURN            820..823
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   HELIX           826..834
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   HELIX           847..856
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   HELIX           861..863
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   HELIX           867..879
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   HELIX           881..884
FT                   /evidence="ECO:0007829|PDB:6FNK"
FT   HELIX           912..918
FT                   /evidence="ECO:0007829|PDB:2QKQ"
FT   HELIX           922..924
FT                   /evidence="ECO:0007829|PDB:2QKQ"
FT   HELIX           925..930
FT                   /evidence="ECO:0007829|PDB:2QKQ"
FT   HELIX           936..939
FT                   /evidence="ECO:0007829|PDB:2QKQ"
FT   HELIX           944..950
FT                   /evidence="ECO:0007829|PDB:2QKQ"
FT   HELIX           955..965
FT                   /evidence="ECO:0007829|PDB:2QKQ"
SQ   SEQUENCE   987 AA;  108270 MW;  11A004622F194706 CRC64;
     MELRVLLCWA SLAAALEETL LNTKLETADL KWVTFPQVDG QWEELSGLDE EQHSVRTYEV
     CDVQRAPGQA HWLRTGWVPR RGAVHVYATL RFTMLECLSL PRAGRSCKET FTVFYYESDA
     DTATALTPAW MENPYIKVDT VAAEHLTRKR PGAEATGKVN VKTLRLGPLS KAGFYLAFQD
     QGACMALLSL HLFYKKCAQL TVNLTRFPET VPRELVVPVA GSCVVDAVPA PGPSPSLYCR
     EDGQWAEQPV TGCSCAPGFE AAEGNTKCRA CAQGTFKPLS GEGSCQPCPA NSHSNTIGSA
     VCQCRVGYFR ARTDPRGAPC TTPPSAPRSV VSRLNGSSLH LEWSAPLESG GREDLTYALR
     CRECRPGGSC APCGGDLTFD PGPRDLVEPW VVVRGLRPDF TYTFEVTALN GVSSLATGPV
     PFEPVNVTTD REVPPAVSDI RVTRSSPSSL SLAWAVPRAP SGAVLDYEVK YHEKGAEGPS
     SVRFLKTSEN RAELRGLKRG ASYLVQVRAR SEAGYGPFGQ EHHSQTQLDE SEGWREQLAL
     IAGTAVVGVV LVLVVIVVAV LCLRKQSNGR EAEYSDKHGQ YLIGHGTKVY IDPFTYEDPN
     EAVREFAKEI DVSYVKIEEV IGAGEFGEVC RGRLKAPGKK ESCVAIKTLK GGYTERQRRE
     FLSEASIMGQ FEHPNIIRLE GVVTNSMPVM ILTEFMENGA LDSFLRLNDG QFTVIQLVGM
     LRGIASGMRY LAEMSYVHRD LAARNILVNS NLVCKVSDFG LSRFLEENSS DPTYTSSLGG
     KIPIRWTAPE AIAFRKFTSA SDAWSYGIVM WEVMSFGERP YWDMSNQDVI NAIEQDYRLP
     PPPDCPTSLH QLMLDCWQKD RNARPRFPQV VSALDKMIRN PASLKIVARE NGGASHPLLD
     QRQPHYSAFG SVGEWLRAIK MGRYEESFAA AGFGSFELVS QISAEDLLRI GVTLAGHQKK
     ILASVQHMKS QAKPGTPGGT GGPAPQY
//
